spacer
home > ebr > spring 2002 > prevention and cure - intellectual property due diligence and warranties in biotechnology and pharmaceutical technology transfer agreements
PUBLICATIONS
European Biopharmaceutical Review

Prevention and Cure - Intellectual Property Due Diligence and Warranties in Biotechnology and Pharmaceutical Technology Transfer Agreements

Part one of this article, which appeared in the last edition of EBR (1), was concerned with the function and importance of intellectual property due diligence in the context of biotechnology and pharmaceutical technology transfer agreements. Having looked at this crucial aspect of the pre-contract process, this second part of the series focuses on the closely related topic of contractual warranties and considers some 'frequently asked questions'.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Daniel Pavin, a Solicitor Specialising in Intellectual Property and Information Technology Law with Taylor Joynson Garrett

Daniel Pavin is a Solicitor specialising in intellectual property and information technology law. Daniel advises a wide range of clients, and has a particular focus on clients in the pharmaceutical, biotechnology and information technology sectors. He has a Diploma in Intellectual Property Law and Practice from Bristol University, UK.

Daniel has a degree from Cambridge University in Computer Science and Physics and worked as a Computer Programmer before qualifying as a Solicitor.

spacer
Daniel Pavin
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Data custodianship of connected devices, environmental impact and adherence technologies highlighted at Pharmapack Europe 2020

Paris, 19th February 2020: Improving adherence to medication via smarter, patient-centric pharmaceutical packaging and extracting further value from existing medicines and delivery devices are two of the latest key strategies aimed at reducing waste and protecting the bottom line, according to experts at the recent Pharmapack Europe (#pharmapackeu). The event is widely seen as an excellent yardstick of the industry’s prospects for the year ahead. Encouragingly, the event played host a record 411 exhibiting companies, 5366 attendees and 325 delegates.
More info >>

White Papers

Value-Added Processing and Quality By Design Principles Help Meet High-Quality Demands

West Pharmaceutical Services, Inc.

The current pharmaceutical market has faced a variety of challenges, including increasing expectations for quality from end-users and regulatory agencies driven by concern for patient safety. While pharmaceutical companies are working to assure that new quality and compliance paradigms are met, a balance must be achieved between the reality of managing costs in an effort to provide a product that meets the requirements of payers along with facilitating profitability in order to continue adequate business reinvestment.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement